title: Prognostic value of dual-time-point 18F-FDG PET-CT imaging in patients with head and neck squamous cell carcinoma.
abstract: OBJECTIVE
  The objective of this study was to investigate the independent prognostic value of dual-time-point (18)F-fluorodeoxyglucose ((18)F-FDG) PET-CT imaging in patients with head and neck squamous cell carcinoma (HNSCC).
  
  
  METHODS
  Patients referred to our department to undergo (18)F-FDG PET-CT for staging of HNSCC were prospectively included. Each patient was scanned using a Philips Gemini PET-CT system 1 h (early acquisition) and 2 h (delayed acquisition) after injection. An intratumoral retention index (RI) of (18)F-FDG was measured for each examination by the dual-time-point method. Event-free survival (EFS) and overall survival (OS) were determined by the Kaplan-Meier method and compared with the conventional maximum standardized uptake value (SUV(max)) at 60 min, SUV(max) at 120 min, and RI in univariate and multivariate analyses including the usual prognostic factors such as age, sex, primary site, SCC histologic grade, and American Joint Committee on Cancer stage (I, II, III, and IV).
  
  
  RESULTS
  Sixty-six consecutive patients (60 men and six women; mean age=61 ± 9 years) were included in the study. In univariate analysis, besides age and stage, RI was predictive of EFS (P=0.01) but not of OS (P=0.1), whereas SUV(max) at 60 min was not predictive of EFS (P=0.18) or OS (P=0.08) and SUV(max) at 120 min was predictive of OS (P=0.02) but not of EFS (P=0.05). In multivariate analysis, RI persisted as an independent predictive factor for EFS (P=0.02) but not SUV(max) at 120 min for OS (P=0.12).
  
  
  CONCLUSIONS
  Our results suggest an additional prognostic interest of RI measured by dual-time-point (18)F-FDG PET-CT, independent of usual prognostic factors, in patients with HNSCC.
authors.affiliation: Department of Nuclear Medicine, University Hospital of Brest, Brest, France. ronan.abgral@gmail.com
authors.forename: Ronan
authors.initials: R
authors.lastname: Abgral
authors.forename: Pierre-Yves
authors.initials: PY
authors.lastname: Le Roux
authors.forename: Jean
authors.initials: J
authors.lastname: Rousset
authors.forename: Solène
authors.initials: S
authors.lastname: Querellou
authors.forename: Gérald
authors.initials: G
authors.lastname: Valette
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Nowak
authors.forename: Alexandre
authors.initials: A
authors.lastname: Turzo
authors.forename: Valentin
authors.initials: V
authors.lastname: Tissot
authors.forename: Rémi
authors.initials: R
authors.lastname: Marianowski
authors.forename: Pierre-Yves
authors.initials: PY
authors.lastname: Salaün
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging* / Q000473:pathology; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D015999:Multivariate Analysis; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011379:Prognosis; D012737:Sex Factors; D013997:Time Factors; D014057:Tomography, X-Ray Computed
chemical_list: D019788:Fluorodeoxyglucose F18